Cardiology · 3 h ago
More Intensive Lipid Lowering Produces Greater Coronary Plaque Regression
A prespecified secondary imaging analysis of the randomized FLOWPROMOTE trial included 104 statin-naive patients with stable coronary artery disease. At 18 months, rosuvastatin plus ezetimibe lowered LDL cholesterol more and reduced total and noncalcified plaque volumes more than atorvastatin alone.
- Combination therapy lowered LDL cholesterol by 65%.
- Total and noncalcified plaque regressed more with combination therapy.
- Calcified plaque volume increased similarly in both groups.
- The analysis measured imaging outcomes, not cardiovascular events.
FLOWPROMOTE was a multicenter randomized trial in statin-naive patients with newly diagnosed stable coronary artery disease. This secondary imaging analysis included 104 participants who received either atorvastatin 40 mg daily or rosuvastatin 40 mg plus ezetimibe 10 mg for 18 months. Coronary CT angiography was performed at baseline and at 9 and 18 months; prespecified outcomes included changes in total, noncalcified and calcified plaque volumes across the coronary arteries.
At 18 months, LDL cholesterol fell by 38% with atorvastatin and 65% with the combination regimen, to 69.5 and 42.5 mg/dL, respectively. Total plaque volume decreased by 13.6% with atorvastatin and 21.1% with combination therapy; the between-group difference was −30.9 mm³ (95% CI, −57.2 to −4.5; P=.02). Noncalcified plaque volume fell by 20.0% and 28.2%, respectively (difference, −28.9 mm³; 95% CI, −53.2 to −4.6; P=.02). Calcified plaque volume increased similarly in both groups.
The findings indicate greater regression of CT-measured plaque burden with more intensive LDL lowering in this population. The analysis involved 104 patients and assessed imaging outcomes; it does not establish whether the observed differences reduce cardiovascular events or apply to other patient groups.
In practice
For statin-naive patients with newly diagnosed stable coronary artery disease resembling this trial population, adding ezetimibe to high-intensity statin therapy produced greater reductions in CT-measured total and noncalcified plaque than atorvastatin alone over 18 months. This supports the potential for more intensive LDL lowering to reduce plaque burden, but the analysis was small and evaluated imaging surrogates rather than cardiovascular events. It does not establish that treatment should be changed for patients outside the studied population.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
JAMA Cardiology: Intensive vs More Intensive Lipid-Lowering Therapy and Plaque Regression in Statin-Naive Patients ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.